Portal hypertension laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Portal hypertension}}
{{Portal hypertension}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}
{{PleaseHelp}}


==Overview==
==Overview==


==Laboratory Findings==
==Laboratory Findings==
*There are no diagnostic laboratory findings exclusively associated with portal hypertension.
*Laboratory findings related with the diagnosis of cirrhosis, as the most common underlying disease for portal hypertension, include indirect serum markers and direct fibrosis markers.
=== Indirect serum markers ===
==== Platelet count ====
* Reduced platelet count is the most frequent test used to diagnose portal hypertension in chronic liver disease.<ref name="pmid23058320">{{cite journal |vauthors=Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, García-Pagán JC, Pinzani M, Bosch J |title=Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis |journal=Gastroenterology |volume=144 |issue=1 |pages=102–111.e1 |year=2013 |pmid=23058320 |doi=10.1053/j.gastro.2012.10.001 |url=}}</ref>
* 78% of the patients with cirrhosis have thrombocytopenia.<ref name="pmid19281860">{{cite journal |vauthors=Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R, Rendon G |title=Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis |journal=Clin. Gastroenterol. Hepatol. |volume=7 |issue=6 |pages=689–95 |year=2009 |pmid=19281860 |pmc=4545534 |doi=10.1016/j.cgh.2009.02.021 |url=}}</ref>
* The probability of esophageal varices are low when the platelet count is normal.<ref name="pmid26047908">{{cite journal |vauthors=de Franchis R |title=Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension |journal=J. Hepatol. |volume=63 |issue=3 |pages=743–52 |year=2015 |pmid=26047908 |doi=10.1016/j.jhep.2015.05.022 |url=}}</ref>
==== ALT/AST index ====
==== AST/platelet ratio index ====
==== Lok ====
==== FIB-4 ====
==== Forns ====
=== Direct fibrosis markers ===
==== Fibrotest ====
==== Fibrometer ====
==== Hepascore ====
==== Hyaluronic acid ====
==== Enhanced liver fibrosis ====
*An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
*Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].


==References==
==References==

Revision as of 21:00, 2 November 2017

Portal Hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Portal Hypertension from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Portal hypertension laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Portal hypertension laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Portal hypertension laboratory findings

CDC on Portal hypertension laboratory findings

Portal hypertension laboratory findings in the news

Blogs on Portal hypertension laboratory findings

Directions to Hospitals Treating Portal hypertension

Risk calculators and risk factors for Portal hypertension laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Laboratory Findings

  • There are no diagnostic laboratory findings exclusively associated with portal hypertension.
  • Laboratory findings related with the diagnosis of cirrhosis, as the most common underlying disease for portal hypertension, include indirect serum markers and direct fibrosis markers.

Indirect serum markers

Platelet count

  • Reduced platelet count is the most frequent test used to diagnose portal hypertension in chronic liver disease.[1]
  • 78% of the patients with cirrhosis have thrombocytopenia.[2]
  • The probability of esophageal varices are low when the platelet count is normal.[3]

ALT/AST index

AST/platelet ratio index

Lok

FIB-4

Forns

Direct fibrosis markers

Fibrotest

Fibrometer

Hepascore

Hyaluronic acid

Enhanced liver fibrosis

  • An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
  • Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

References

  1. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, García-Pagán JC, Pinzani M, Bosch J (2013). "Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis". Gastroenterology. 144 (1): 102–111.e1. doi:10.1053/j.gastro.2012.10.001. PMID 23058320.
  2. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R, Rendon G (2009). "Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis". Clin. Gastroenterol. Hepatol. 7 (6): 689–95. doi:10.1016/j.cgh.2009.02.021. PMC 4545534. PMID 19281860.
  3. de Franchis R (2015). "Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension". J. Hepatol. 63 (3): 743–52. doi:10.1016/j.jhep.2015.05.022. PMID 26047908.

Template:WH Template:WS